patritumab
bezlotoxumab
iratumumab
soravtansine
tigatuzumab
countercorrelated
anticorrelate
antipolyvalent
idiospecific
-toxa-
pancytokeratin
reagin
chromobody
naptumomab estafenatox
-ab
conatumumab
samalizumab
antigenomic
vobarilizumab
oleclumab
tenatumomab
immunoprobe
panitumumab
immunoinflammation
ozogamicin
tabalumab
autoantibody
agonistic monoclonal antibody
pathoantigen
guselkumab
agglutinin
bococizumab
ipilimumab
alloantibody
seroblock
-o-
antiserum
immunospecific
figitumumab
drozitumab
-a-
serospecific
antiplasma
antiidiotypic
presentation
vepalimomab
acrixolimab
lucatumumab
volociximab
antigenic